CD34 expression on bone marrow blasts is a novel predictor of poor prognosis independent of FlT3-ITD in acute myeloid leukemia with the NPM1-mutation

Leukemia Research

Volumn 37, Issue 6, 2013, Pages 624-630

  Zhu, Hong Hu ^a   Liu, Yan Rong ^a   Jiang, Hao ^a   Lu, Jin ^a   Qin, Ya Zhen ^a   Jiang, Qian ^a   Bao, li ^a   Ruan, Guo Rui ^a   Jiang, Bin ^a   Huang, Xiaojun ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Acute myeloid leukemia; CD34; FLT3 ITD; Nucleophosmin mutation; Prognosis

Indexed keywords

ANTHRACYCLINE; CD135 ANTIGEN; CD34 ANTIGEN; CYTARABINE; DAUNORUBICIN; IDARUBICIN; NUCLEOPHOSMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW BLAST; CANCER PROGNOSIS; DISEASE FREE SURVIVAL; FEMALE; GENE DUPLICATION; GENE MUTATION; HEMATOPOIETIC SYSTEM; HUMAN; INTERNAL TANDEM DUPLICATION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; BONE MARROW CELLS; CHILD; FEMALE; FMS-LIKE TYROSINE KINASE 3; GRANULOCYTE PRECURSOR CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PROGNOSIS; SURVIVAL ANALYSIS; TANDEM REPEAT SEQUENCES; YOUNG ADULT;

EID: 84877018020     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.02.007     Document Type: Article

References (34)

1. Falini B., Mecucci C., Tiacci E., Alcalay M., Rosati R., Pasqualucci L., et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005, 352(3):254-266.
2. Schnittger S., Schoch C., Kern W., Mecucci C., Tschulik C., Martelli M.F., et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005, 106(12):3733-3739.
3. Mori Y., Yoshimoto G., Kumano T., Miyamoto T., Lino T., Takenaka K., et al. Distinctive expression of myelomonocytic markers and down-regulation of CD34 in acute myelogenous leukaemia with FLT3 tandem duplication and nucleophosmin mutation. Eur J Haematol 2007, 79(1):17-24.
4. Döhner K., Schlenk R.F., Habdank M., Scholl C., Rücker F.G., Corbacioglu A., et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005, 106(12):3740-3746.
5. Falini B., Martelli M.P., Bolli N., Sportoletti P., Liso A., Tiacci E., et al. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?. Blood 2011, 117(4):1109-1120.
6. Arber D.A., Brunning R.D., Le Beau M.M., Falini B., Vardiman J.W., Porwit A., et al. Acute myeloid leukemia with recurrent genetic abnormalities. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, 110-123. International Agency for Research on Cancer, Lyon, France. S.H. Swerdlow, E. Campo, N.L. Harris (Eds.).
7. Thiede C., Koch S., Creutzig E., Steudel C., Illmer T., Schaich M., et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006, 107(10):4011-4020.
8. Paschka P., Schlenk R.F., Gaidzik V.I., Habdank M., Krönke J., Bullinger L., et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010, 28(22):3636-3643.
9. Krönke J., Schlenk R.F., Jensen K.O., Tschürtz F., Corbacioglu A., Gaidzik V.I., et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. J Clin Oncol 2011, 29(19):2709-2716.
10. Repp R., Schaekel U., Helm G., Thiede C., Soucek S., Pascheberg U., et al. Immunophenotyping is an independent factor for risk stratification in AML. Cytometry B Clin Cytom 2003, 53(1):11-19.
11. Chang H., Salma F., Yi Q.L., Patterson B., Brien B., Minden M.D. Prognostic relevance of immunophenotype in 379 patients with acute myeloid leukemia. Leuk Res 2004, 28(1):43-48.
12. Jiang A., Jiang H., Brandwein J., Kamel-Reid S., Chang H. Prognostic factors in normal karyotype acute myeloid leukemia in the absence of the FLT3-ITD mutation. Leuk Res 2011, 35(4):492-498.
13. Junghanss C., Waak M., Knopp A., Kleine H.D., Kundt G., Leithäuser M., et al. Multivariate analyses of prognostic factors in acute myeloid leukemia: relevance of cytogenetic abnormalities and CD34 expression. Neoplasma 2005, 52(5):402-410.
14. Raspadori D., Lauria F., Ventura M.A., Rondelli D., Visani G., de V.A., et al. Incidence and prognostic relevance of CD34 expression in acute myeloblastic leukemia: analysis of 141 cases. Leuk Res 1997, 21(7):603-607.
15. Röllig C., Thiede C., Gramatzki M., Aulitzky W., Bodenstein H., Bornhäuse M.L., et al. A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. Blood 2010, 116(6):971-978.
16. Plesa C., Chelghoum Y., Plesa A., Elhamri M., Tigaud I., Michallet M., et al. Prognostic value of immunophenotyping in elderly patients with acutemyeloid leukemia: a single-institution experience. Cancer 2008, 112(3):572-580.
17. Zhu H.H., Jiang B., Lu X.J., Jiang Q., Jiang H., Bao L., et al. The clinical characteristics of newly diagnosed acute myeloid leukemia patients with NPM1 mutation. Zhonghua Xue Ye Xue Za Zhi 2010, 3(5):315-318.
18. Chou W.C., Tang J.L., Lin L.I., Yao M., Tsay W., Chen C.Y., et al. Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution. Cancer Res 2006, 66(6):3310-3316.
19. Oelschlaegel U., Mohr B., Schaich M., Schäkel U., Kroschinsky F., Illmer T., et al. HLA-DRneg patients without acute promyelocytic leukemia show distinct immunophenotypic, genetic, molecular, and cytomorphologic characteristics compared to acute promyelocytic leukemia. Cytometry B Clin Cytom 2009, 76(5):321-327.
20. Dohner H., Estey E.H., Amadori S., Appelbaum F.R., Büchner T., Burnett A.K., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood 2010, 115(3):453-474.
21. Cheson B.D., Bennett J.M., Kopecky K.J., Büchner T., Willman C.L., Estey E.H., et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003, 21(24):4642-4649.
22. Lucio P., Gaipa G., van Lochem E.G., van Wering E.R., Porwit-MacDonald A., Faria T., et al. BIOMED-I. BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 concerted action investigation of minimal residual disease in acute leukemia:international standardization and clinical evaluation. Leukemia 2001, 15(8):1185-1192.
23. Ruan G.R., Li J.L., Qin Y.Z., Li L.D., Xie M., Chang Y., et al. Nucleophosmin mutations in Chinese adults with acule myelogenous leukemia. Ann Hematol 2009, 88(2):59-166.
24. Qin Y.Z., Zhu H.H., Jiang B., Li J.L., Lu X.J., Li L.D., et al. Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease. Leuk Res 2009, 33(3):384-390.
25. Huang X.J., Zhu H.H., Chang Y.J., Xu L.P., Liu D.H., Zhang X.H., et al. The superiority of haploidentical related stem cell transplantation to chemotherapy alone as post-remission treatment for patients with intermediate- or high- risk acute myeloid leukemia in first complete remission. Blood 2012, 119(23):5584-5590.
26. Metz C.E. Basic principles of ROC analysis. Semin Nucl Med 1978, 8(4):283-298.
27. Schneider F., Hoster E., Unterhalt M., Schneider S., Dufour A., Benthaus T., et al. NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS). Blood 2009, 113(21):5250-5253.
28. Gale R.E., Green C., Allen C., Mead A.J., Burnett A.K., Hills R.K., et al. The impact of FLT3 internal tandem duplication mutant level, number, size and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008, 111(5):2776-2784.
29. Dalal B.I., Wu V., BarnettMJ, Horsman D.E., Spinelli J.J., Naiman S.C., et al. Induction failure in de novo acute myelogenous leukemia is associated with expression of high levels of CD34 antigen by the leukemic blasts. Leuk Lymphoma 1997, 26(3-4):299-306.
30. Suarez L., VidrialesMB, Garcia-Larana J., SanzG, MorenoMJ, Lopez A., et al. CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes. Clin Cancer Res 2004, 10(22):7599-7606.
31. Choudhary C., Schwable J., Brandts C., Tickenbrock L., Sargin B., Kindler T., et al. AML associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. Blood 2005, 106(1):265-273.
32. Marcucci G., Maharry K., Wu Y.Z., Radmacher M.D., Mrózek K., Margeson D., et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010, 28(14):2348-2355.
33. Schnittger S., Haferlach C., Ulke M., Alpermann T., Kern W., Haferlach T. IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood 2010, 116(25):5486-5496.
34. Abbas S., Lugthart S., Kavelaars F.G., Schelen A., Koenders J.E., Zeilemaker A., et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia (AML): prevalence and prognostic value. Blood 2010, 116(12):2122-2126.